{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:02:05Z","timestamp":1789970525868,"version":"4.0.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"\n Background<\/jats:title>\n Direct comparative evidence on the effectiveness of telitacicept versus belimumab in active systemic lupus erythematosus (SLE) remains limited. This study aimed to compare their effectiveness and safety in patients with active SLE.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This retrospective cohort study included 91 patients with active SLE treated at Affiliated Hospital of Nantong University between July 2021 and June 2024. Eligible patients received conventional therapy and were treated with belimumab (n=45) or telitacicept (n=46) for 24 weeks. Inverse probability of treatment weighting (IPTW) was applied to balance baseline covariates. The primary outcome was the proportion of patients achieving LLDAS at week 24.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Telitacicept was associated with significantly better outcomes than belimumab in achieving LLDAS at week 24 (30.92% vs. 11.35%,\n P<\/jats:italic>\n \u00a0=\u00a00.026) and SRI-4 responses at weeks 12 and 24 (both\n P<\/jats:italic>\n \u00a0&lt;\u00a00.01). The steroid-sparing effect also favored telitacicept, as evidenced by higher proportions of patients achieving prednisone reduction to \u22645 mg\/d (40.99% vs. 18.72%,\n P<\/jats:italic>\n \u00a0&lt;\u00a00.05) and \u22647.5 mg\/d (52.14% vs. 27.25%,\n P<\/jats:italic>\n \u00a0&lt;\u00a00.05). Additionally, telitacicept led to a significantly greater reduction in SLEDAI-2K score from baseline at both time points. In contrast, no significant between-group differences were observed in serological indicators. In exploratory multivariable analysis, telitacicept treatment (OR 4.975,\n P<\/jats:italic>\n \u00a0=\u00a00.006), higher SLEDAI-2K score (OR 1.316,\n P<\/jats:italic>\n \u00a0=\u00a00.016), and shorter disease duration (OR 0.914,\n P<\/jats:italic>\n \u00a0=\u00a00.031) were independently associated with SRI-4 response at week 24. Both treatments showed numerically low adverse event rates, with no serious events reported.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Telitacicept was associated with higher weighted response rates than belimumab in this single-center retrospective cohort of patients with active SLE after the reported adjustment.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1927886","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:35:01Z","timestamp":1789968901000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and safety of belimumab and telitacicept in active systemic lupus erythematosus: a retrospective cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Yi","family":"Shao","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, Affiliated Hospital of Nantong University","place":["Nantong, China"]},{"name":"Department of Rheumatology and Immunology, Nantong Tongzhou Eighth People\u2019s Hospital","place":["Nantong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidan","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Affiliated Hospital of Nantong University","place":["Nantong, China"]},{"name":"Medical School of Nantong University","place":["Nantong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Affiliated Hospital of Nantong University","place":["Nantong, China"]},{"name":"Medical School of Nantong University","place":["Nantong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Affiliated Hospital of Nantong University","place":["Nantong, China"]},{"name":"Medical School of Nantong University","place":["Nantong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfeng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Affiliated Hospital of Nantong University","place":["Nantong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Jing","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Affiliated Hospital of Nantong University","place":["Nantong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Affiliated Hospital of Nantong University","place":["Nantong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanyun","family":"Da","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Affiliated Hospital of Nantong University","place":["Nantong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5714","DOI":"10.3390\/jcm14165714","article-title":"Autoantibodies in systemic lupus erythematosus: Diagnostic and pathogenic insights","volume":"14","author":"Pagkopoulou","year":"2025","journal-title":"J Clin Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)30237-5","article-title":"Management strategies and future directions for systemic lupus erythematosus in adults","volume":"393","author":"Durcan","year":"2019","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41392-025-02168-0","article-title":"Systemic lupus erythematosus: Updated insights on the pathogenesis, diagnosis, prevention and therapeutics","volume":"10","author":"Dai","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223035","article-title":"Global epidemiology of systemic lupus erythematosus: A comprehensive systematic analysis and modelling study","volume":"82","author":"Tian","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2478\/rir-2022-0006","article-title":"The challenges and future perspective for the management of systemic lupus erythematosus in China: A concise annual report of 2020","volume":"3","author":"Tian","year":"2022","journal-title":"Rheumatol Immunol Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.5114\/reum.2022.115667","article-title":"2022 systemic lupus erythematosus remission in clinical practice. Message for Polish rheumatologists","volume":"60","author":"Pawlak-Bu\u015b","year":"2022","journal-title":"Reumatologia"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e001766","DOI":"10.1136\/lupus-2025-001766","article-title":"Validation of proposals for definitions of moderate and severe disease activity in SLE: Impact on flares, quality of life, damage accrual, hospitalisations and mortality","volume":"12","author":"Altab\u00e1s-Gonz\u00e1lez","year":"2025","journal-title":"Lupus Sci Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1515\/rir-2025-0017","article-title":"2025 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus","volume":"6","author":"Zhao","year":"2025","journal-title":"Rheumatol Immunol Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13075-024-03389-4","article-title":"Use of belimumab in treating patients with systemic lupus erythematosus: A single-center, real-world retrospective study","volume":"26","author":"Su","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s10238-025-01640-z","article-title":"Evaluation of the efficacy and safety of belimumab and telitacicept in patients with systemic lupus erythematosus: Results from a retrospective, observational study","volume":"25","author":"Feng","year":"2025","journal-title":"Clin Exp Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211631","article-title":"A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea","volume":"77","author":"Zhang","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/08923973.2021.1973493","article-title":"Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease","volume":"43","author":"Shi","year":"2021","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2414719","article-title":"A phase 3 trial of telitacicept for systemic lupus erythematosus","volume":"393","author":"van Vollenhoven","year":"2025","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224854","article-title":"Telitacicept in patients with active systemic lupus erythematosus: Results of a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"83","author":"Wu","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e001074","DOI":"10.1136\/lupus-2023-001074","article-title":"Efficacy and safety of telitacicept in patients with systemic lupus erythematosus: A multicentre, retrospective, real-world study","volume":"10","author":"Jin","year":"2023","journal-title":"Lupus Sci Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e001217","DOI":"10.1136\/lupus-2024-001217","article-title":"Characterisation and outcomes of different subsets of low disease activity states in patients with systemic lupus erythematosus","volume":"11","author":"Hao","year":"2024","journal-title":"Lupus Sci Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2018-000288","article-title":"Clinical response beyond the systemic lupus erythematosus responder index: Post-hoc analysis of the BLISS-SC study","volume":"5","author":"van Vollenhoven","year":"2018","journal-title":"Lupus Sci Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e001156","DOI":"10.1136\/lupus-2024-001156","article-title":"Combination of anti-SSA\/Ro60 and anti-dsDNA serotype is predictive of belimumab renal response in patients with lupus nephritis","volume":"11","author":"Zhao","year":"2024","journal-title":"Lupus Sci Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224919","article-title":"Pragmatic targets for moderate\/severe SLE and their implications for clinical care and trial design: Sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression","volume":"83","author":"Pitsigavdaki","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-024-07266-y","article-title":"Effectiveness and safety of belimumab and telitacicept in systemic lupus erythematosus: A real-world, retrospective, observational study","volume":"44","author":"Jin","year":"2025","journal-title":"Clin Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae041","article-title":"A path to glucocorticoid stewardship: A critical review of clinical recommendations for the treatment of systemic lupus erythematosus","volume":"63","author":"Bertsias","year":"2024","journal-title":"Rheumatol (Oxford)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2147\/btt.S551578","article-title":"The potential of telitacicept in treating lupus erythematosus panniculitis: A case report","volume":"19","author":"Xie","year":"2025","journal-title":"Biologics"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"2019 update of the joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e001747","DOI":"10.1136\/rmdopen-2021-001747","article-title":"Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: An across-study comparison","volume":"7","author":"Brunner","year":"2021","journal-title":"RMD Open"},{"key":"B28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ard.2025.09.007","article-title":"EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update","volume":"85","author":"Fanouriakis","year":"2026","journal-title":"Ann Rheum Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1927886\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:35:02Z","timestamp":1789968902000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1927886\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2026.1927886"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1927886","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"article-number":"1927886"}}